June 1, 2022 12:17 am EDT

Organon (NYSE: OGN) – a company focused on the health and wellbeing of women has marked National Sorry Day by adding its signature to support the Uluru Statement from the Heart, which calls for the establishment of a First Nations Voice in the Constitution and a Makarrata Commission on agreement-making and truth-telling between Aboriginal and Torres Strait Islander peoples and governments.

Nirelle Tolstoshev, managing director of Organon in Australia said, “We launched Organon globally with a promise to listen to and act on women’s experiences to address the challenges in women’s health. The Uluru Statement from the Heart also calls for First Nations People’s voices to be heard, and we believe that action is needed to address the inequities which continue to be experienced by Aboriginal and Torres Strait Island peoples.

“The Uluru Statement represents an invitation for all Australians to come together in a national dialogue that will help to positively shape our national identity, and by signing the Uluru Statement from the Heart, we are clearly signalling that First Nations voices matter and should be heard.

Organon was established and listed on the New York Stock Exchange in June 2021. “One of the early conversations we had with our Founders in Australia was about reconciliation with First Nations people and developing a Reconciliation Action Plan, which we are currently working towards. In the meantime, we wanted to show our commitment by signing the Statement from the Heart on this important day.

“We encourage other pharmaceutical and healthcare companies across the country to join us in this important conversation,” Tolstoshev concluded.

To learn more about Organon, please visit http://www.organon.com/australia and connect with us on LinkedIn.

About Organon
Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.